The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features the return of Richard Clowater, President of GEMXX Corp. (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone and jewelry production.

To begin the interview, Clowater expounded on a recent news release detailing why the company’s management team feels GEMXX is currently undervalued.

“Since its inception, GEMXX has always looked for resource assets that are commercially viable. To date, we’ve acquired five properties, but only one of those properties has a partial assessment known as an S-K 1300, which is a report produced by a qualified professional,” Clowater explained. “These reports offer comprehensive insights into mineral resources, reserves, exploration, outcome and the technical intricacies of a project. That being said, the report is not required to determine if a property is a good acquisition – if you have enough mining experience.”

Bell2Bell’s latest podcast features the return of Richard Clowater, President of GEMXX Corp. (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone and jewelry production.

To begin the interview, Clowater expounded on a recent news release detailing why the company’s management team feels GEMXX is currently undervalued.

“Since its inception, GEMXX has always looked for resource assets that are commercially viable. To date, we’ve acquired five properties, but only one of those properties has a partial assessment known as an S-K 1300, which is a report produced by a qualified professional,” Clowater explained. “These reports offer comprehensive insights into mineral resources, reserves, exploration, outcome and the technical intricacies of a project. That being said, the report is not required to determine if a property is a good acquisition – if you have enough mining experience.”

Bell2Bell’s latest podcast features Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD), along with Buzz Woods from Corporate Communications, who join the podcast to share insights into the biopharmaceutical company's groundbreaking work in novel anti-purinergic drug therapies (APT) for neurologic conditions, primarily Autism Spectrum Disorder (ASD).

Explore the comprehensive interview on the Bell2Bell Podcast, where PaxMedica, Inc., a prominent clinical-stage biopharmaceutical firm, provides valuable perspectives on its innovative initiatives and visionary advancements in the sphere of novel anti-purinergic drug therapies. Gain an exclusive understanding of PaxMedica's pioneering efforts in neurology and biopharmaceutical breakthroughs, with a special emphasis on advancements in treating Autism Spectrum Disorder (ASD) and other neurologic conditions, as Howard Weisman, Chairman and CEO, and Buzz Woods from Corporate Communications, offer a compelling overview of the company's recent achievements and future objectives.

Join the highly acclaimed host, Bell2Bell's Stuart Smith, and Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD) and Buzz Woods Corporate Communications, to learn more about the company’s recent milestones and operational goals for the balance of 2023 and beyond.

Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.

This episode was recorded live at the venue hosting the 2023 American Association for Cancer Research Conference for Molecular Targets and Cancer Therapeutics, one of the premier conferences in the field. The conference serves as a platform for researchers, clinicians, and industry professionals to present and discuss the latest breakthroughs in cancer research.

Dr. Berger provided valuable insights into Genprex's recent groundbreaking achievements, particularly focusing on the promising data presented at the conference. He delved into the positive implications of the Acclaim-1 Phase 1 study, shedding light on the absence of Dose Limiting Toxicity and the potential impact of REQORSA® in the treatment of non-small cell lung cancer (NSCLC). Additionally, he discussed the upcoming Acclaim-3 clinical trial and the preclinical data in small cell lung cancer (SCLC), highlighting its significance in advancing SCLC treatment.

To gain a comprehensive understanding of Genprex's recent milestones and its transformative impact on cancer treatment, be sure to tune in to this informative episode.

Bell2Bell’s latest podcast features Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD), along with Buzz Woods from Corporate Communications, who join the podcast to share insights into the biopharmaceutical company's groundbreaking work in novel anti-purinergic drug therapies (APT) for neurologic conditions, primarily Autism Spectrum Disorder (ASD).

Explore the comprehensive interview on the Bell2Bell Podcast, where PaxMedica, Inc., a prominent clinical-stage biopharmaceutical firm, provides valuable perspectives on its innovative initiatives and visionary advancements in the sphere of novel anti-purinergic drug therapies. Gain an exclusive understanding of PaxMedica's pioneering efforts in neurology and biopharmaceutical breakthroughs, with a special emphasis on advancements in treating Autism Spectrum Disorder (ASD) and other neurologic conditions, as Howard Weisman, Chairman and CEO, and Buzz Woods from Corporate Communications, offer a compelling overview of the company's recent achievements and future objectives.

Join the highly acclaimed host, Bell2Bell's Stuart Smith, and Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD) and Buzz Woods Corporate Communications, to learn more about the company’s recent milestones and operational goals for the balance of 2023 and beyond.

Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.

This episode was recorded live at the venue hosting the 2023 American Association for Cancer Research Conference for Molecular Targets and Cancer Therapeutics, one of the premier conferences in the field. The conference serves as a platform for researchers, clinicians, and industry professionals to present and discuss the latest breakthroughs in cancer research.

Dr. Berger provided valuable insights into Genprex's recent groundbreaking achievements, particularly focusing on the promising data presented at the conference. He delved into the positive implications of the Acclaim-1 Phase 1 study, shedding light on the absence of Dose Limiting Toxicity and the potential impact of REQORSA® in the treatment of non-small cell lung cancer (NSCLC). Additionally, he discussed the upcoming Acclaim-3 clinical trial and the preclinical data in small cell lung cancer (SCLC), highlighting its significance in advancing SCLC treatment.

To gain a comprehensive understanding of Genprex's recent milestones and its transformative impact on cancer treatment, be sure to tune in to this informative episode.

Bell2Bell’s latest podcast features Rob Etherington, President and CEO of Clene Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

To begin the interview, Etherington provided an introduction to Clene’s business model and discussed recent developments providing hope to those affected by neurodegenerative conditions.

“Clene spends every waking moment working on amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative condition. We are focused on neurodegenerative diseases generally – including multiple sclerosis and Parkinson’s – but our body of evidence that has really come to the forefront in the last few years has been all around ALS,” Etherington explained. “The timing is important because this remains a remarkably devastating disease with life mortality of 3-5 years from diagnosis. It remains uniformly and universally fatal… It’s just devastating and tragic.”

Bell2Bell’s latest podcast features Rob Etherington, President and CEO of Clene Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

To begin the interview, Etherington provided an introduction to Clene’s business model and discussed recent developments providing hope to those affected by neurodegenerative conditions.

“Clene spends every waking moment working on amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative condition. We are focused on neurodegenerative diseases generally – including multiple sclerosis and Parkinson’s – but our body of evidence that has really come to the forefront in the last few years has been all around ALS,” Etherington explained. “The timing is important because this remains a remarkably devastating disease with life mortality of 3-5 years from diagnosis. It remains uniformly and universally fatal… It’s just devastating and tragic.”

Bell2Bell’s latest podcast features Richard Clowater, President of GEMXX Corp. (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone and jewelry production.

To begin the interview, Clowater provided an introduction to Ammolite, an extremely rare gemstone of which GEMXX is a leading producer.

“Ammolite is a very rare gemstone. It’s similar to black opal when you look at it; it’s very iridescent and features a kaleidoscope of colors. You can actually find every color of the rainbow in a single gemstone,” Clowater explained. “The really interesting part about the gemstone is where it comes from. It’s the fossilized shell of a creature called an Ammonite, an ancient sea nautilus. Now, Ammolite gemstone and Ammonite fossils are only found along the eastern slopes of the Rocky Mountains in southern Alberta, Canada, fossilized into this beautiful gemstone. Because it’s only found in one place and it’s so highly sought-after, it’s considered to be one of the rarest gems on earth.”

Clowater then turned his attention to GEMXX’s business model and leadership team.

“GEMXX is a mine-to-market enterprise, and we aspire to be fully integrated. This means that we must wear a lot of hats in this business model. We’re a resource exploration company, and we have over $800 million in reserves. We currently mine gold, and we’re very excited to hopefully open the world’s largest Ammolite mine by the end of this year. After operating several mines in the area over the last 30 years, our experience will allow us to move quickly on that operation… We also manufacture all of our own products, and we’re a wholesaler of gold, finished gemstones and fine jewelry, as well as being a retailer of our finished products around the world in any areas that don’t have representation by our retailers.”

“All of us have been in the industry for a long time. We are grateful to have a management team with over 160 years of combined experience in gold, gemstone production, operations and sales. Our mining experts have decades of experience getting gold and Ammolite gemstone out of the earth, and mining Ammolite is no easy task… It’s our experts that provide a competitive edge in every facet of our business, allowing us to excel in product development, maintain rigorous quality control and maximize profitability.”

Join IBN’s Stuart Smith and Richard Clowater, President of GEMXX Corp. (OTC: GEMZ), to learn more about the company’s recent milestones and operational goals for the balance of 2023 and beyond.

Bell2Bell’s latest podcast features Richard Clowater, President of GEMXX Corp. (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone and jewelry production.

To begin the interview, Clowater provided an introduction to Ammolite, an extremely rare gemstone of which GEMXX is a leading producer.

“Ammolite is a very rare gemstone. It’s similar to black opal when you look at it; it’s very iridescent and features a kaleidoscope of colors. You can actually find every color of the rainbow in a single gemstone,” Clowater explained. “The really interesting part about the gemstone is where it comes from. It’s the fossilized shell of a creature called an Ammonite, an ancient sea nautilus. Now, Ammolite gemstone and Ammonite fossils are only found along the eastern slopes of the Rocky Mountains in southern Alberta, Canada, fossilized into this beautiful gemstone. Because it’s only found in one place and it’s so highly sought-after, it’s considered to be one of the rarest gems on earth.”

Clowater then turned his attention to GEMXX’s business model and leadership team.

“GEMXX is a mine-to-market enterprise, and we aspire to be fully integrated. This means that we must wear a lot of hats in this business model. We’re a resource exploration company, and we have over $800 million in reserves. We currently mine gold, and we’re very excited to hopefully open the world’s largest Ammolite mine by the end of this year. After operating several mines in the area over the last 30 years, our experience will allow us to move quickly on that operation… We also manufacture all of our own products, and we’re a wholesaler of gold, finished gemstones and fine jewelry, as well as being a retailer of our finished products around the world in any areas that don’t have representation by our retailers.”

“All of us have been in the industry for a long time. We are grateful to have a management team with over 160 years of combined experience in gold, gemstone production, operations and sales. Our mining experts have decades of experience getting gold and Ammolite gemstone out of the earth, and mining Ammolite is no easy task… It’s our experts that provide a competitive edge in every facet of our business, allowing us to excel in product development, maintain rigorous quality control and maximize profitability.”

Join IBN’s Stuart Smith and Richard Clowater, President of GEMXX Corp. (OTC: GEMZ), to learn more about the company’s recent milestones and operational goals for the balance of 2023 and beyond.